Compare Quest Diagnostics Inc (DGX) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Stanley Black & Decker, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.21 (market cap $22.80B), while Stanley Black & Decker, Inc. trades at $88.08 (market cap $13.58B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| DGX | SWK | |
|---|---|---|
Market Cap | $22.80B | $13.58B |
Sector | Health | — |
52-Week High | $216.02 | $94.12 |
52-Week Low | $166.42 | $62.12 |
Enterprise Value | $28.82B | $19.75B |
Dividend Yield | 1.67% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Stanley Black & Decker (SWK) trades at $86.53, down 1.92% on the day, with a bearish technical signal but recent earnings beats. The company shows modest revenue of $15.13B in 2025 and a net income margin of 2.44%, though profitability metrics like ROE at 4.17% remain subdued. A dividend of $0.83 was recently declared, with cash flow from operations positive at $971.20M. Analyst consensus is mixed with 43% buy ratings but a price target below the current price.
SWK faces headwinds from weak Tools & Outdoor demand and high debt, though cost-saving efforts and aerospace growth offer upside. The stock's valuation at a P/E of 35.46 appears stretched relative to earnings growth, suggesting cautious optimism hinges on execution improvements and debt reduction. Risks include consumer sentiment and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
